GSK Wins Broad Label Expansion for Jemperli in First-Line Endometrial Cancer

In pursuit of Merck’s blockbuster Keytruda, GSK’s Jemperli scored its own broad FDA label expansion, allowing its use in the first-line endometrial cancer regardless of biomarker status.